KQB168 + pembrolizumab

KQB168 + pembrolizumab is an investigational **oral small molecule immunotherapy (KQB168)** in combination with **pembrolizumab**, a monoclonal antibody checkpoint inhibitor targeting PD-1, being developed for the treatment of advanced solid tumor malignancies in adults who have progressed on immunotherapy. KQB168 is administered daily orally, and pembrolizumab is administered intravenously. The mechanism of KQB168 has not been publicly detailed; pembrolizumab blocks the interaction between PD-1 and its ligands (PD-L1, PD-L2), thereby activating T lymphocytes to target tumor cells. The combination is in early-phase clinical trials to investigate safety, optimal dosing, pharmacokinetics, and anti-tumor efficacy[1][2][3][4].